Passage Bio Inc. (PASG)
Passage Bio Inc. (PASG) Stock Price, Analysis & Data
| Bid | 3.23 |
| Market Cap | 14.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.68M |
| Beta | 1.43 |
| EPS (ttm) | -11.32 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.44 |
| P/B (ttm) | 0.78 |
| P/S (ttm) | n/a |
| Earnings Date | Mar 3, 2026 |
| Ask | 5.76 |
| Volume | 6,163 |
| Avg. Volume (20D) | 71,167 |
| Open | 4.50 |
| Previous Close | 4.50 |
| Day's Range | 4.43 - 4.67 |
| 52-Week Range | 3.29 - 20.00 |
| Analyst | Buy |
| Price Target | 15.5 (237.69%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PASG
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystr...
Financial Performance
In 2025, Passage Bio's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -45.52M, a decrease of -29.71%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for PASG stock is "Buy". The 12-month stock price forecast is 15.5, which is upside of 237.69% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
